Enliven Therapeutics (ELVN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.49
- Estimate
- -$0.36
- Surprise
- -37.4%
- Score today
- 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Enliven Therapeutics (ELVN) reported a wider loss than forecast — diluted EPS of -$0.49 against the -$0.36 estimate (a 37.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ELVN Sell at 5.0/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -37.4% surprise compares with a +1.9% four-quarter average. Next scheduled report: 2026-11-11.
What argues against it
- Concentration risk — Pipeline: ELVN-001
- Concentration risk — Supplier: Pharmaron
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $57.89
- Price target
- $64.29
- Stop
- $54.64
- Upside to target
- +11.1%
- Reward-to-risk
- 1.6:1
Model outputs from TrendMatrix’s engine as of 2026-09-01 — shown for context, not personalized investment advice.
ELVN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.24B
- P/E (fwd)
- -24.7
- 52-week range
- $14.79–$62.32
- Off 52-week high
- 7.1%
- RSI (14)
- 45
- Volume vs avg
- 1.02×
- Score today
- 5.0/10